273 related articles for article (PubMed ID: 27452461)
1. Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.
Kurimchak AM; Shelton C; Duncan KE; Johnson KJ; Brown J; O'Brien S; Gabbasov R; Fink LS; Li Y; Lounsbury N; Abou-Gharbia M; Childers WE; Connolly DC; Chernoff J; Peterson JR; Duncan JS
Cell Rep; 2016 Aug; 16(5):1273-1286. PubMed ID: 27452461
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer.
Kurimchak AM; Shelton C; Herrera-Montávez C; Duncan KE; Chernoff J; Duncan JS
Mol Cancer Res; 2019 Aug; 17(8):1721-1734. PubMed ID: 31043489
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.
Stuhlmiller TJ; Miller SM; Zawistowski JS; Nakamura K; Beltran AS; Duncan JS; Angus SP; Collins KA; Granger DA; Reuther RA; Graves LM; Gomez SM; Kuan PF; Parker JS; Chen X; Sciaky N; Carey LA; Earp HS; Jin J; Johnson GL
Cell Rep; 2015 Apr; 11(3):390-404. PubMed ID: 25865888
[TBL] [Abstract][Full Text] [Related]
4. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
[TBL] [Abstract][Full Text] [Related]
5. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
[TBL] [Abstract][Full Text] [Related]
6. KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity.
Qiang Y; Fan J; Xie C; Yan L; Song X; Zhang N; Lin Y; Xiong J; Zhang W; Liu Y; Wei L; Li Y; Chen S; Liang K; Li F
Cancer Res; 2024 Apr; 84(8):1252-1269. PubMed ID: 38285760
[TBL] [Abstract][Full Text] [Related]
7. Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells.
Quintela M; James DW; Pociute A; Powell L; Edwards K; Coombes Z; Garcia J; Garton N; Das N; Lutchman-Singh K; Margarit L; Beynon AL; Rioja I; Prinjha RK; Harker NR; Gonzalez D; Conlan RS; Francis LW
Clin Epigenetics; 2023 Apr; 15(1):63. PubMed ID: 37060086
[TBL] [Abstract][Full Text] [Related]
8. Enhanced JunD/RSK3 signalling due to loss of BRD4/FOXD3/miR-548d-3p axis determines BET inhibition resistance.
Tai F; Gong K; Song K; He Y; Shi J
Nat Commun; 2020 Jan; 11(1):258. PubMed ID: 31937753
[TBL] [Abstract][Full Text] [Related]
9. Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms.
Shi X; Mihaylova VT; Kuruvilla L; Chen F; Viviano S; Baldassarre M; Sperandio D; Martinez R; Yue P; Bates JG; Breckenridge DG; Schlessinger J; Turk BE; Calderwood DA
Proc Natl Acad Sci U S A; 2016 Aug; 113(31):E4558-66. PubMed ID: 27432991
[TBL] [Abstract][Full Text] [Related]
10. Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.
Villar-Prados A; Wu SY; Court KA; Ma S; LaFargue C; Chowdhury MA; Engelhardt MI; Ivan C; Ram PT; Wang Y; Baggerly K; Rodriguez-Aguayo C; Lopez-Berestein G; Ming-Yang S; Maloney DJ; Yoshioka M; Strovel JW; Roszik J; Sood AK
Mol Cancer Ther; 2019 Feb; 18(2):421-436. PubMed ID: 30420565
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
Saenz DT; Fiskus W; Mill CP; Perera D; Manshouri T; Lara BH; Karkhanis V; Sharma S; Horrigan SK; Bose P; Kadia TM; Masarova L; DiNardo CD; Borthakur G; Khoury JD; Takahashi K; Bhaskara S; Lin CY; Green MR; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
Blood; 2020 Apr; 135(15):1255-1269. PubMed ID: 32068780
[TBL] [Abstract][Full Text] [Related]
12. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
13. The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.
Ma Y; Wang L; Neitzel LR; Loganathan SN; Tang N; Qin L; Crispi EE; Guo Y; Knapp S; Beauchamp RD; Lee E; Wang J
Clin Cancer Res; 2017 Apr; 23(8):2027-2037. PubMed ID: 27678457
[No Abstract] [Full Text] [Related]
14. BET Proteins as Attractive Targets for Cancer Therapeutics.
Sarnik J; Popławski T; Tokarz P
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681760
[TBL] [Abstract][Full Text] [Related]
15. Bromodomain-Containing Protein BRD4 Is Hyperphosphorylated in Mitosis.
Wang R; Yang JF; Ho F; Robertson ES; You J
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32575711
[TBL] [Abstract][Full Text] [Related]
16. Loss of VOPP1 Contributes to BET Inhibitor Acquired Resistance in Non-Small Cell Lung Cancer Cells.
Sun L; Wu Q; Huan XJ; Tian CQ; Wang YQ; Miao ZH
Mol Cancer Res; 2022 Dec; 20(12):1785-1798. PubMed ID: 36001806
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
18. Targeting CCR2
Wu Y; Jennings NB; Sun Y; Dasari SK; Bayraktar E; Corvigno S; Stur E; Glassman D; Mangala LS; Lankenau Ahumada A; Westin SN; Sood AK; Hu W
J Cancer Res Clin Oncol; 2022 Apr; 148(4):803-821. PubMed ID: 35094142
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response.
Conery AR; Centore RC; Spillane KL; Follmer NE; Bommi-Reddy A; Hatton C; Bryant BM; Greninger P; Amzallag A; Benes CH; Mertz JA; Sims RJ
Cancer Res; 2016 Mar; 76(6):1313-9. PubMed ID: 26759243
[TBL] [Abstract][Full Text] [Related]
20. Concurrent targeting of MAP3K3 and BRD4 by
Liu C; Gen Y; Tanimoto K; Muramatsu T; Inoue J; Inazawa J
Mol Ther Nucleic Acids; 2021 Sep; 25():83-92. PubMed ID: 34258104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]